The effects of atorvastatin therapy on endothelıal function in patients with coronary artery disease
| Autor: | Ahmet Yildiz, M Akif Cakar, Ugur Coskun, Murat Başkurt, Barış Ökçün, Deniz Güzelsoy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty lcsh:Diseases of the circulatory (Cardiovascular) system Endothelium Atorvastatin Coronary Disease medicine.disease_cause Coronary Angiography Coronary artery disease chemistry.chemical_compound Internal medicine medicine.artery medicine Humans Radiology Nuclear Medicine and imaging Pyrroles cardiovascular diseases Brachial artery Angiology Ultrasonography biology business.industry Cholesterol Anticholesteremic Agents C-reactive protein General Medicine Middle Aged medicine.disease medicine.anatomical_structure C-Reactive Protein Treatment Outcome chemistry Radiology Nuclear Medicine and imaging lcsh:RC666-701 Heptanoic Acids biology.protein Cardiology lipids (amino acids peptides and proteins) Female Endothelium Vascular Technical Notes business Cardiology and Cardiovascular Medicine Oxidative stress medicine.drug |
| Zdroj: | Cardiovascular Ultrasound Cardiovascular Ultrasound, Vol 5, Iss 1, p 51 (2007) |
| ISSN: | 1476-7120 |
| Popis: | Background Statins improve the endothelial function in patients with coronary artery disease (CAD). However, they contribute to the substantial decrease in coronary heart disease by reducing plasma cholesterol levels. They also, reduce oxidative stress, stabilize the atherosclerotic plaque and inhibit inflammatory response. These functions of statins have been briefly described as pleiotropic effects. The aim of our study was to evaluate the effect of atorvastatin therapy on endothelial functions in patients with CAD. Methods Fourty-nine patients (40 men, 9 women, mean age 59 +/- 11 years) with diagnosed CAD were selected as the study group. The patients were given 10 mg/day atorvastatin for 12 weeks. If the target cholesterol levels has not been achieved 6 weeks after the treatment, then the daily atorvastatin dosage has been increased. The endothelial function was evaluated by flow mediated dilatation (FMD) of the brachial artery. Results It has been figured out that 12 weeks later, atorvastatin caused a statistically significant decrease in the plasma levels of LDL-cholesterol and total cholesterol (p < 0,0001). Meanwhile, it was determined that the FMD got statistically significant improved 12 weeks after the atorvastatin therapy (8,1%–4,2%, p < 0,001). However there was no statistically significant change in non-endothelium dependent dilatation (NID). Conclusion Endothelium derived vasodilatation (EBD), which was non-invasively detected via brachial artery ultrasonography, had statistically significant improvment within 12 weeks of atorvastatin therapy whereas non-endothelium dependent dilatation (NID) had no change. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|